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Abstract The peptide N-acetyl-CRATKML-amide is an e¡ec-
tive inhibitor of type A botulinum neurotoxin (BoNT A) pro-
tease activity [Schmidt et al., FEBS Lett. 435 (1998) 61^64]. To
improve inhibitor binding, the peptide was modi¢ed by replacing
cysteine with other sulfhydryl-containing compounds. Ten pep-
tides were synthesized. One peptide adapted the structure of
captopril to the binding requirements of BoNT A, but it was
a weak inhibitor, suggesting that angiotensin-converting enzyme
is not a good model for BoNT A inhibitor development. How-
ever, replacing cysteine with 2-mercapto-3-phenylpropionyl
yielded a peptide with Ki of 330 nM, the best inhibitor of
BoNT A protease activity reported to date. Additional modi¢-
cations of the inhibitor revealed structural elements important
for binding and supported our earlier ¢ndings that, with the
exception of P1P arginine, subsites on BoNT A are not highly
speci¢c for particular amino acid side chains.
< 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Botulinum neurotoxins (BoNTs) are produced by various
strains of the anaerobic spore-forming bacilli Clostridium bo-
tulinum, C. butyricum and C. baratii [1^3]. There are seven
serotypes, A^G [4]. Each neurotoxin consists of a heavy chain
(Mr V100 000) and a light chain (Mr V50 000), covalently
linked by a single disul¢de bond. The heavy chain includes
domains for binding to peripheral motor neurons and toxin
internalization, while the light chain is a zinc metalloprotease,
speci¢c for proteins involved in acetylcholine release. BoNTs
A, C, and E cleave synaptosomal-associated protein of Mr
25 000 (SNAP-25), while synaptobrevin is the target of B,
D, F, and G. In addition to SNAP-25, BoNT C also cleaves
syntaxin. Each neurotoxin hydrolyzes only a single bond in its
substrate, but this is su⁄cient to prevent exocytosis of neuro-
transmitter [5,6].
Botulinum neurotoxins are among the most potent toxins
known [7]. Nonetheless, they have proven to be useful tools in
neurophysiology studies [4,8,9] and as drugs to treat certain
muscle dysfunctions and other diseases in humans [7,10^13].
Therefore, considerable interest in BoNTs has developed with
regard to catalytic properties [14^16], three-dimensional struc-
tures [17^20], BoNT internalization and intracellular process-
ing [5], and development of speci¢c inhibitors to reverse or
modulate BoNT-induced paralysis [21^23].
In earlier work, we developed a practical high-performance
liquid chromatography (HPLC)-based assay for BoNT A pro-
tease activity, and unequivocally demonstrated that the
‘SNARE motifs’ [24,25] in SNAP-25 are not required for
BoNT A substrate recognition [15]. We then employed the
assay to characterize the catalytic properties of BoNT A
[16], and used this information to obtain the ¢rst speci¢c
competitive inhibitors of BoNT A protease activity [22]. In
this report, we describe development of the ¢rst BoNT A
inhibitor with Ki in the nanomolar range, present ¢ndings
on the contributions of inhibitor side chains to binding a⁄n-
ity, and discuss implications of our results with respect to
further BoNT A inhibitor development.
2. Materials and methods
2.1. Peptide synthesis
The peptide synthesizer was a model 431A from Applied Biosys-
tems (Foster City, CA, USA). We used reagents and protocols ob-
tained from the same source. Peptides were synthesized as C-terminal
amides, and puri¢ed by reverse phase HPLC with gradients of aceto-
nitrile in 0.1% tri£uoroacetic acid (TFA). Equipment for HPLC was
from Waters Corporation (Milford, MA, USA). HPLC columns (Hi-
Pore RP318 and RP304) were from Bio-Rad Laboratories (Hercules,
CA, USA).
In the peptides synthesized for this study, the N-terminal moieties
contained sulfhydryl groups and were not standard amino acids. In
some cases, the appropriate S-protected compounds were commer-
cially available from Calbiochem-Novabiochem (San Diego, CA,
USA) or Bachem (King of Prussia, PA, USA). Others were custom-
synthesized by Bachem. Because custom syntheses of N-terminal in-
termediates containing optically active carbons were not stereospe-
ci¢c, each subsequent peptide yielded a racemic mixture, which was
then puri¢ed by HPLC. The earlier-eluting stereoisomer was desig-
nated peptide A, while the later was peptide B.
2.2. Assay of BoNT A protease activity
BoNT A was obtained from Metabiologics (Madison, WI, USA).
Assays of BoNT A protease activity were performed as described
previously [15,16]. Brie£y, assays (30 Wl) contained 20 mM HEPES,
pH 7.3, 1 mg/ml bovine serum albumin, 5 mM dithiothreitol, 0.25
mM ZnCl2, various concentrations of substrate (a peptide corre-
sponding to residues 187^203 of SNAP-25), and 1 Wg/ml BoNT A.
The temperature was 37‡C. Assays were stopped by adding TFA to
0.5%, then analyzed by reverse-phase HPLC. Concentrations of sub-
strates and hydrolysis products were calculated from peak areas.
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Kinetic constants were obtained from plots of initial rates with
seven concentrations of substrate. Results were calculated from non-
linear regression analyses by using the program Enz¢tter (Biosoft,
Cambridge, UK). Values are the averages of three independent deter-
minations. In all cases, standard deviations were less than S20%. Ki
values for the inhibitors were calculated in triplicate from Dixon plots
with the equation: Ki =Km/[(slope)(Vmax)[S]], where [S] is the substrate
concentration [26]. For the best inhibitor, Ki and the type of inhibi-
tion were also evaluated by determining substrate kinetic constants in
the presence of ¢ve di¡erent inhibitor concentrations. Ki values for
each of the ¢ve assays in the presence of inhibitor were calculated with
the equation: Ki = [I]/[(Kmapp/Km)31], where [I] is inhibitor concentra-
tion [26].
3. Results and discussion
3.1. Ki values of the inhibitors
In our earlier report [22], we presented evidence that
the relatively strong binding of the BoNT A inhibitor
CRATKML (Ki = 2 WM) was probably due to binding of
BoNT A active site zinc by the N-terminal cysteine sulfhydryl
group. Therefore, to obtain an inhibitor of BoNT A with
lower Ki than CRATKML, we retained the sulfhydryl but
modi¢ed other aspects of the N-terminal moiety. Two strat-
egies were employed: (1) the sulfhydryl was kept on the
L carbon, and the amino on the K carbon was replaced with
hydrogen and with other groups; (2) the K amino was elimi-
nated, the sulfhydryl was moved to the K carbon, and the
L carbon was modi¢ed. After synthesizing each compound,
it was attached through an amide bond to the N-terminus
of the peptide RATKML, and the Ki value of the product
was determined. Results for peptides containing representative
compounds from the two groups are shown in Table 1.
Peptide 1 in Table 1 has 2-methyl-3-mercaptopropionyl as
the N-terminal moiety. This peptide is included in the table
because it can be considered an analog of the anti-hyperten-
sion drug captopril, which is N-(2-methyl-3-mercaptopropion-
yl)-proline [27]. Captopril binds tightly (Ki = 0.3 nM) to its
target protein, angiotensin-converting enzyme, a zinc carboxy-
dipeptidase [27]. However, captopril was reported to be a
weak inhibitor of BoNT protease activity [28,29], probably
because none of the botulinum toxins can bind proline near
the active site. Therefore, we anticipated that replacing the
proline in captopril with RATKML would adapt the molecule
to ¢t the binding requirements of BoNT A and yield a good
inhibitor. However, neither the A nor the B isomer of peptide
1 had a lower Ki relative to our earlier inhibitor [22]. We
concluded that angiotensin-converting enzyme is not a good
model for development of BoNT A protease inhibitors.
The N-terminal moiety of peptide 2 retains the sulfhydryl
group on the L carbon, but the K and L carbons are included
in a cyclohexane ring. Introducing a cyclic structure was an
attempt to decrease rotational freedom (lower entropy) and
thereby enhance binding of the peptide, a common strategy
for developing enzymatic inhibitors [30,31]. However, neither
peptide 2A nor 2B bound strongly to BoNT A.
In contrast to the above results, transfer of the sulfhydryl to
the K carbon yielded high-a⁄nity inhibitors of BoNT A pro-
tease activity. Peptide 3A, with 2-mercaptopropionyl as the
N-terminal moiety, exhibited a modest but signi¢cant im-
provement in Ki, compared to the cysteine peptide. This ¢nd-
ing suggested that an K sulfhydryl was in a more favorable
position for binding the active site zinc compared to a
L sulfhydryl. A phenyl ring was then added to the L carbon
to produce peptide 4. The later-eluting stereoisomer, 4B, had
the lowest Ki value of any BoNT A inhibitor described to
date, 0.3 WM.
Finally, a methylene group was added to the carbon chain
of the N-terminal moiety to yield peptide 5. However, we were
unable to separate the two peptide stereoisomers, probably
because of increased rotational freedom caused by the length-
ened carbon chain. The Ki value of the 5A+5B mixture was
2 WM (Table 1), while that for an equimolar mixture of 4A
and 4B was 0.7 WM. If we assume that the two stereoisomers
of peptide 5 were present in equimolar amounts (which was
true for all other peptides in this study), it is unlikely that
either 5A or 5B has a Ki value lower than that of 4B.
Other peptides with various N-terminal moieties were syn-
thesized and tested, but are not shown in Table 1. They in-
cluded peptides where X was: 3-mercaptopropionyl, thiogly-
colyl, L-homocysteinyl, L-penicillaminyl, and D-penicillaminyl.
Ki values ranged from 2 WM to greater than 10 mM (data not
shown).
3.2. N-terminal conformations of peptides 3 and 4
The N-terminus of peptide 3 is an analog of alanine, with
sulfhydryl on the K carbon instead of an amino group. Sim-
ilarly, peptide 4 N-terminus is an analog of phenylalanine.
Peptides XRATKML were synthesized where X was L-ala-
Table 1
Structures of N-terminal moieties and Ki values of peptide deriva-
tives
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nine, D-alanine, L-phenylalanine, and D-phenylalanine. Ki val-
ues for these peptides were 6, 18, 20, and 150 WM, respec-
tively, showing that within each pair, the peptide with the
L-amino acid at the N-terminus was a more e¡ective inhibitor
than the corresponding D-amino acid peptide. HPLC reten-
tion time of L-ARATKML was earlier than the D-peptide,
but the converse was true for the two stereoisomers of
FRATKML. This pattern was mirrored precisely by the ster-
eoisomers of peptides 3 and 4, i.e. the best inhibitors were the
earlier-eluting 3A and the later-eluting 4B. Therefore, we con-
cluded that the absolute conformations about the N-terminal
alpha carbons in peptides 3A and 4B probably correspond to
the L-forms of naturally occurring amino acids.
3.3. Peptide 4A is a competitive inhibitor of BoNT A protease
activity
Because Dixon plots do not indicate the type of inhibition
(competitive, non-competitive, or uncompetitive), we com-
pared kinetic constants determined for the 17-residue peptide
substrate alone to those obtained in the presence of ¢ve con-
centrations of peptide 4B. Results are shown in Table 2. Pep-
tide 4B had no e¡ect on Vmax, but Kmapp increased with
inhibitor concentration. Therefore, peptide 4B was a
competitive inhibitor of BoNT A protease activity. The aver-
age Ki was 330S 50 nM. Preincubating BoNT A with peptide
4B for up to 30 min had no e¡ect on the extent of inhibition,
compared to that observed when BoNT A was simultaneously
exposed to substrate and inhibitor. Therefore, the Ki value for
peptide 4B probably represents equilibrium binding of inhib-
itor to enzyme (data not shown).
3.4. E¡ects of inhibitor peptide length and amino acid
substitutions on Ki values
In earlier work [22], we obtained good inhibition of BoNT
A protease activity by substituting cysteine for P1 glutamine
in the 17-residue substrate peptide. We then found that elim-
inating all the residues on the N-terminal side of the cysteine
had no e¡ect on inhibitor binding. In this study, we deter-
mined the contributions to binding of residues on the C-ter-
minal side of the 2-mercapto-3-phenylpropionyl (mpp) group
(which corresponds to the substrate P1 residue) by synthesiz-
ing and testing truncated versions of peptide 4. Ki values for
the B-isomers, which in all cases were lower than those of the
A-isomers, are shown in Table 3. Both mpp-R and mpp-RA
had the same Ki, 60 WM, while adding threonine lowered it by
50%. However, additions of the lysine and methionine resi-
dues had the strongest e¡ects on Ki, with approximately sev-
en-fold and 10-fold decreases, respectively. Including leucine
and GSG, the last four residues of SNAP-25, had no e¡ect on
Ki.
In the inhibitors, residues RATKM correspond to the P1P
through P5P residues of the substrate. To investigate further
the binding contribution of each amino acid side chain, we
substituted other amino acids, one substitution per peptide, at
these locations in peptide 4B (Table 3). Because of their rel-
atively strong contributions to inhibitor binding a⁄nity, the
e¡ects of replacing P5P methionine and P4P lysine were of
particular interest. However, substitution of alanine for me-
thionine caused only a small increase in Ki, suggesting that the
presence of a peptide bond in that location was of more con-
sequence than the structure of the side chain. Replacing lysine
with alanine caused a 10-fold increase in Ki, but this was less
drastic than might have been expected, given the substitution
of a small hydrophobic residue for a large positively charged
amino acid and the importance of the P4P residue for binding.
Similar results were found when P3P threonine was replaced
with alanine, and P2P alanine with the branched amino acid
valine. In contrast, P1P arginine could not be replaced by
lysine (shown) or alanine or citrulline (not shown) without
drastic loss of binding.
In summary, these ¢ndings support our earlier conclusion
that, with the exception of P1P arginine, BoNT A does not
have absolute requirements for particular side chains with
respect to binding of substrates or inhibitors [16,22]. In pep-
tide 4B, the major contributors to binding a⁄nity are the
sulfhydryl group (presumably binding the active site zinc),
the phenyl ring, the arginine side chain, and the peptide back-
bone of the ¢rst ¢ve amino acids. Therefore, it is unlikely that
an inhibitor with signi¢cantly lower Ki would result from
replacements of RATKM in peptide 4 with other amino acids,
either individually or in combinations. Similarly, the improve-
ment in binding a⁄nity obtained by adding the phenyl ring to
peptide 3 to yield peptide 4 could not have been anticipated,
because the subsite on BoNT A for side chains at this location
(equivalent to the P1 residue of the substrate) was also shown
to be non-speci¢c with respect to binding [16,22].
Nonetheless, the work described herein has resulted in the
most e¡ective inhibitor of BoNT A protease activity to date:
peptide 4B, with Ki of 330 nM. Because it is a competitive
inhibitor, peptide 4B will prove useful in studies of BoNT A
active site and interactions with substrate, through X-ray
analyses of BoNT A^peptide 4B cocrystals. It will also serve
as a model for further development of inhibitors with en-
hanced binding and improved biostability properties, from
additional modi¢cations to the N-terminal moiety and re-
placement of the other residues with non-amino acid com-
Table 2
E¡ects of inhibitor on substrate kinetic constants
[I]a (WM) Vmax (Wmol/min/mg) Kmapp (mM) Ki (WM)
0 15 1.3
0.087 14 1.6 0.37
0.16 14 2.1 0.27
0.26 15 2.4 0.30
0.33 14 2.5 0.36
0.61 16 4.3 0.27
a[I] is peptide 4B, mpp-RATKML.
Table 3
E¡ects of inhibitor peptide length and amino acid substitutions on
Ki
Inhibitor Kia (WM)
mpp-R 60
mpp-RA 60
mpp-RAT 30
mpp-RATK 4
mpp-RATKM 0.3
mpp-RATKML 0.3
mpp-RATKMLGSG 0.3
mpp-RATKAL 0.7
mpp-RATAML 3
mpp-RAAKML 0.7
mpp-RVTKML 2
mpp-KATKML s 300
aKi values are for the B-stereoisomers.
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pounds. A wide range of modi¢cations must be evaluated, and
the work extended to include other BoNT serotypes. To this
end, we have developed true high-throughput assays for the
protease activities of BoNTs A, B, D, and F [32], and work on
similar assays for serotypes C, E, and G is in progress.
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